Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
Emerging research suggests that hormone therapy has no significant impact upon the diagnostic efficacy of 18F-piflufolastat PET/CT for detecting recurrent or metastatic prostate cancer. For the retrospective study, recently published in The Prostate, researchers evaluated the use of 18F-piflufolastat PET/CT (Pylarify, Lantheus) in 93 patients with elevated prostate-specific antigen (PSA) levels and suspected local recurrence … Read more